Absence of transforming growth factor-β type II receptor is associated with poorer prognosis in HER2-negative breast tumours
- 13 November 2009
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 21 (4), 734-740
- https://doi.org/10.1093/annonc/mdp518
Abstract
Background: The clinical relevance of transforming growth factor-beta (TGF-β)-signalling pathway in breast carcinomas (BCs) remained elusive. This study aimed to evaluate the prognostic value of TGF-β1 and transforming growth factor-beta type II receptor (TGF-βRII) expression levels in tumour cells and their association with the established biomarkers in BC. Patients and methods: In 324 BC from patients with long-term follow-up, the TGF-β1 and TGF-βRII transcript and protein expression levels were assessed. Results: TGF-β1 and TGF-βRII down-expression was significantly associated with BC. Negative TGF-β1 and TGF-βRII protein status was associated with the development of distant metastasis (P = 0.003 and P = 0.029, respectively). In multivariate analysis, TGF-β1-positive tumours were associated with increased disease-free survival (DFS) [hazard ratio (HR) = 0.489, P = 0.003]. TGF-βRII positivity was an independent prognostic factor for DFS (HR = 0.439, P = 0.001) and overall survival (OS) (HR = 0.409, P = 0.003) in human epidermal growth factor receptor-2 (HER2)-negative patients. Absence of TGF-β1 and TGF-βRII proteins in breast tumour cells was significantly associated with metastasis development. Conclusions: To the best of our knowledge, this is the first report indicating the relevance of HER2 status in discriminating TGF-βRII as a prognostic marker for DFS and OS in human BC. These data indicate that TGF-βRII protein analysis in tumour cells could be introduced in clinical practice as additional prognostic biomarker in HER2-negative BC.Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2007/52632-0)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico-Ministério da Saúde–DECIT (401196/2005-4)
This publication has 24 references indexed in Scilit:
- Transforming growth factor-β signaling: emerging stem cell target in metastatic breast cancer?Breast Cancer Research and Treatment, 2008
- TGFβ in CancerCell, 2008
- Evaluation of estrogen receptor α and β and progesterone receptor expression and correlation with clinicopathologic factors and proliferative marker Ki-67 in breast cancersHuman Pathology, 2008
- Transforming growth factor‐β signaling in cancer invasion and metastasisInternational Journal of Cancer, 2007
- Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?Nature Reviews Cancer, 2007
- Determination of TGFβ1 protein level in human primary breast cancers and its relationship with survivalBritish Journal of Cancer, 2006
- HER-2 overexpression differentially alters transforming growth factor-β responses in luminal versus mesenchymal human breast cancer cellsBreast Cancer Research, 2005
- Increased Malignancy of Neu-Induced Mammary Tumors Overexpressing Active Transforming Growth Factor β1Molecular and Cellular Biology, 2003
- Transforming Growth Factor-β and Breast Cancer Risk in Women With Mammary Epithelial HyperplasiaJNCI Journal of the National Cancer Institute, 1999
- Study of tumor infiltrating lymphocytes and transforming growth factor-β as prognostic factors in breast carcinomaInternational Journal of Cancer, 1997